Nasus Pharma enrolls first patient in Phase 1 trial of NS003 intranasal ondansetron formulation
NSRX•Nasus Pharma enrolled and dosed the first patient in a Phase 1 trial of NS003. The study will assess its pharmacokinetics and safety, with topline results expected before year-end.
1. Phase 1 trial begins
Nasus Pharma enrolled and dosed the first patient in a Phase 1 trial of NS003, an intranasal ondansetron product candidate. The study will generate first-in-human pharmacokinetic and safety readouts, with topline results expected before year-end. Preclinical work showed drug exposure broadly comparable to IV ondansetron, with supportive safety findings at higher-than-test dosing.
